Drug discovery and development process aims to make available medications that are safe and effective in improving the length and quality of life and relieving suffering. It comprises of lead discovery and lead optimization. Lead investigational compounds that survive initially are optimized or altered to make them more effective and safer by giving it different properties. In the present work, the carboxylic group of salicylic acid has been derivatized in order to improve its safety profile while maintaining anti-inflammatory and analgesic activity as their most common side effects are the occurrence of gastrointestinal damage with gastric upset and irritation, ulceration, bleeding and renal toxicity. Gastrointestinal damage is attributed to two factors-local irritation by carboxylic acid moiety and decreased cytoprotective PG production. In normal practice, chemotherapeutic, analgesic and anti-inflammatory are prescribed simultaneously which enhances the risk for developing NSAIDs related complications. It is known that bacterial infections often produce pain and inflammation. Hence there is a pressing need of the drugs having both anti- microbial and analgesic, anti- inflammatory activities with minimum side effects. 1,2,4-triazoles and 1,3,4-thiadiazoles both possess wide spectrum of therapeutic activities like antibacterial, antifungal, antiviral, analgesic, anti-inflammatory, anticonvulsant, antidepressant, antihypertensive, and hypoglycemic and diuretic properties. In view of aforementioned reports, Salicylic acid based triazolothiadiazole derivatives were synthesized through Microwave Assisted Organic Synthesis (MAOS) which is considered as an important approach towards green chemistry, because this technique is more environment-friendly and it accelerates the rate of reaction, increase the yield and quality of the product.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 11575 citations as per Google Scholar report